Results 11 to 20 of about 3,471,294 (187)

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales [PDF]

Microbial Drug Resistance, 2022
The objective of this study was to identify putative mechanisms contributing to baseline cefiderocol resistance among carbapenem-resistant Enterobacterales (CRE). We evaluated 56 clinical CRE isolates with no previous exposure to cefiderocol. Cefiderocol
Patricia J Simner, Yehudit Bergman, Andreas E POSCH   +2 more
exaly   +5 more sources

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

Heliyon
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic
Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy   +3 more
doaj   +5 more sources

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

Life, 2023
Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-
Sara Domingues, Tiago Lima, Maria José Saavedra, Gabriela Jorge Da Silva   +3 more
doaj   +6 more sources

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei. [PDF]

Antimicrob Agents Chemother, 2023
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria.
Hall CM, Somprasong N, Hagen JP, Nottingham R, Sahl JW, Webb JR, Mayo M, Currie BJ, Podin Y, Wagner DM, Keim P, Schweizer HP.   +11 more
europepmc   +4 more sources

Contribution of Iron-Transport Systems and β-Lactamases to Cefiderocol Resistance in Clinical Isolates of Acinetobacter baumannii Endemic to New York City. [PDF]

Antimicrob Agents Chemother, 2023
The development of resistance to cefiderocol among multidrug resistant Acinetobacter baumannii has been attributed to downregulation in iron transport systems and a variety of β-lactamases.
Asrat H, Samaroo-Campbell J, Ata S, Quale J.   +3 more
europepmc   +4 more sources

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway

Journal of Global Antimicrobial Resistance, 2023
: Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert, Laura Berneking, Anna Both, Benjamin Berinson, Jiabin Huang, Martin Aepfelbacher, Christine Wolschke, Dominic Wichmann, Holger Rohde   +8 more
doaj   +4 more sources

Killing two birds with one stone: emergence of colistin and cefiderocol resistance in a mucoid MDR <i>Acinetobacter baumannii</i> under colistin pressure. [PDF]

Front Microbiol
Acinetobacter baumannii is a multidrug-resistant (MDR) pathogen associated with nosocomial infections, sporadically detected in cystic fibrosis (CF) patients. Treatment of A. baumannii may be hindered by polysaccharide capsule production of some isolates
Fox V, Vrenna G, Rossitto M, Paris I, Papa R, Artini M, Selan L, Raimondi S, Tuccio Guarna Assanti V, Essa N, Lepanto MS, Cortazzo V, Agosta M, Boni A, Cristiani L, Cutrera R, Perno CF, Bernaschi P.   +17 more
europepmc   +4 more sources

High Prevalence of Cefiderocol Resistance Among New Delhi Metallo-β-Lactamase Producing Klebsiella pneumoniae High-Risk Clones in Hungary [PDF]

Antibiotics
Background/Objectives: The global spread of carbapenemase-producing K. pneumoniae (CPKP) strains represent a severe public health threat due to very limited choice of antibacterial therapy.
Lilla Buzgó, Zsanett Kiss, Dániel Göbhardter, Virág Lesinszki, Erika Ungvári, Zoltán Rádai, Levente Laczkó, Ivelina Damjanova, Gábor Kardos, Ákos Tóth   +9 more
doaj   +3 more sources

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA [PDF]

Clinical Infectious Diseases, 2022
We report a case of resistance development toward cefiderocol in a patient with intra-abdominal and bloodstream infections caused by carbapenemase-producing Enterobacter cloacae within 21 days of cefiderocol therapy.
Sabrina Klein, Sébastien Boutin, Kaan Kocer   +2 more
exaly   +3 more sources

Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol

Current Issues in Molecular Biology
In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB).
Gabriele Bianco, Matteo Boattini, Monica Cricca, Lucia Diella, Milo Gatti, Luca Rossi, Michele Bartoletti, Vittorio Sambri, Caterina Signoretto, Rossella Fonnesu, Sara Comini, Paolo Gaibani   +11 more
doaj   +5 more sources